Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Pyrotinib in HER2+ Digestive Tumors
NCT07053150Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2030
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, pyrotinib in gastric cancer (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), pancreatic cancer (PC), sponsored by Tongji Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
sintilimabpyrotinib
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)biliary tract cancer (BTC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07053150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053150.